Zevra Therapeutics (ZVRA) Stock Price
Zevra Therapeutics Price
Zevra Therapeutics (ZVRA) Stock | ISIN US4884452065 | WKN A2QLX7. The current Zevra Therapeutics stock price is 12.9 USD (2026). Revenue is 147.64 M USD. Net income is 31.87 M USD. The P/E ratio is 18.72. Market capitalization is 726.27 M USD. Zevra Therapeutics operates in the Health sector.
Zevra Therapeutics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Zevra Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Zevra Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Zevra Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Zevra Therapeutics Price |
|---|
Zevra Therapeutics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Zevra Therapeutics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|
| 23 | 102 | 147 | 226 | 305 | 359 | 401 | 431 |
| -14.81 | 343.48 | 44.12 | 53.74 | 34.96 | 17.7 | 11.7 | 7.48 |
| 73.91 | 16.67 | 11.56 | 7.52 | 5.57 | 4.74 | 4.24 | 3.94 |
| 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| -105 | 71 | 31 | 92 | 151 | 186 | 208 | 217 |
| 128.26 | -167.62 | -56.34 | 196.77 | 64.13 | 23.18 | 11.83 | 4.33 |
| 46.25 | 46.25 | 46.25 | 46.25 | 46.25 | 46.25 | 46.25 | 46.25 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Zevra Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Zevra Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Zevra Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Zevra Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Zevra Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Zevra Therapeutics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Zevra Therapeutics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Zevra Therapeutics business model & stock analysis
Zevra Therapeutics SWOT Analysis
Strengths
- Strong intellectual property portfolio, providing a competitive advantage and protecting KemPharm's innovations in drug development.
- Robust pipeline of drug candidates that have shown promising results in early-stage clinical trials.
- Strategic partnerships with leading pharmaceutical companies, enabling access to resources, expertise, and potential collaborations.
- Experienced management team with a track record of successfully developing and commercializing pharmaceutical products.
Weaknesses
- Limited financial resources, which may hinder the company's ability to fully exploit the potential of its pipeline or fund additional clinical trials.
- Relatively small size compared to major pharmaceutical competitors, limiting KemPharm's marketing and distribution capabilities.
- Dependency on the successful development and regulatory approval of its drug candidates, with inherent risks of clinical failures or delays.
- Need for continuous investment in research and development to stay ahead in a highly competitive industry.
Opportunities
- Growing demand for innovative pharmaceuticals to address unmet medical needs and improve patient outcomes.
- Increasing awareness and acceptance of KemPharm's LAT platform technology, attracting potential licensing and partnership opportunities.
- Expansion into global markets, leveraging strategic collaborations and licensing agreements to reach a wider patient population.
- Potential for market exclusivity and revenue growth upon successful regulatory approval of KemPharm's drug candidates.
Threats
- Intense competition within the pharmaceutical industry, with established companies and new entrants vying for market share.
- Stringent regulatory requirements and potential delays in obtaining approvals for new drug candidates.
- Pricing pressures and reimbursement challenges, impacting the profitability and market uptake of KemPharm's products.
- Rapidly evolving technological advancements and shifting market dynamics, necessitating continuous innovation and adaptation.
Zevra Therapeutics Eulerpool Fair Value
Zevra Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio
Zevra Therapeutics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Zevra Therapeutics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Zevra Therapeutics Earnings Estimates
Zevra Therapeutics Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/11/2026 | 0.08USD | 32.6 MUSD | 2026 Q1 |
| 3/9/2026 | 0.05USD | 28.61 MUSD | 2025 Q4 |
| 8/11/2025 | 1.53USD | 22.99 MUSD | 2025 Q2 |
| 11/12/2024 | -0.43USD | 4.97 MUSD | 2024 Q3 |
| 5/13/2024 | -0.41USD | 4.83 MUSD | 2024 Q1 |
| 3/5/2024 | -0.29USD | 11.17 MUSD | 2023 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Zevra Therapeutics stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Zevra Therapeutics shareholder structure
| % | Name |
|---|---|
8.19836% | |
7.4032% | |
6.5997% | |
5.24456% | |
3.90476% | |
3.47836% | |
2.61445% | |
2.20672% | |
2.20543% | |
1.99822% |
Zevra Therapeutics Executives and Management Board
Mr. Neil Mcfarlane
(52)President, Chief Executive Officer, Director · since 2023
Dr. Adrian Quartel
(64)Chief Medical Officer
Mr. Joshua Schafer
(54)Executive Vice President - Business Development, Chief Commercial Officer
Mr. R. LaDuane Clifton
(52)Chief Financial Officer, Treasurer
Dr. Alvin Shih
(47)Independent Director
Frequently asked questions about Zevra Therapeutics
The business model of KemPharm Inc revolves around developing and commercializing innovative medications to address unmet medical needs. As a specialty pharmaceutical company, KemPharm utilizes its proprietary Ligand Activated Therapy (LAT) platform technology to enhance existing drug products, resulting in improved efficacy, safety, and patient compliance. By leveraging this platform, KemPharm aims to provide novel treatment options in various therapeutic areas such as attention-deficit/hyperactivity disorder (ADHD), pain management, and other central nervous system disorders. Through strategic partnerships and collaborations, KemPharm strives to bring valuable medications to market and ultimately contribute to improving patient outcomes and quality of life.
Zevra Therapeutics stock
Zevra Therapeutics Peer Group
Zevra Therapeutics Ticker
Zevra Therapeutics FIGI
All fundamentals and in-depth analysis of Zevra Therapeutics
Our stock analysis for Zevra Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zevra Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.